| October 2009 - Pneumococcal
AMC receives four offers from vaccine manufacturers
The AMC Secretariat is pleased to announce that four suppliers
have made offers to supply vaccines under the Pneumococcal
Advance Market Commitment.
September 2009 - Manufacturers register to participate
in the Pneumococcal AMC
Panacea Biotect Ltd and the Serum institute of India publicly
announced their registration.
First call for offers was issued
on Friday September 4th, 2009
Mid-June 2009, strategic demand forecast
based on this demand forecast UNICEF will issue its first
call for AMC supply offers this summer.
Mid-June 2009, AMC becomes operational
On 12 June, 2009, the Finance Ministers of Italy, the United
Kingdom, Canada, Russia, Norway and the Bill & Melinda
Gates Foundation together with GAVI Alliance partners World
Bank, UNICEF and the World Health Organisation, formally activated
the Advance Market Commitment (AMC) pilot project against
pneumococcal disease.
November 2008, Monitoring & Evaluation Report
Released
(PDF, 780Kb)
July 2008, Implementation Working Group Report
Donors decided to create an Implementation Working Group (IWG)
with the task of recommending a specific proposal for the
AMC structure and parameters. Implementation Working Group
report recommends terms for the pilot Advance Market Commitment
(AMC) for pneumococcal vaccines.
(PDF,
453Kb)
April 2, 2008, Final report of the Economic Expert
Group
The Economic Expert Group issued its report on April 2.
March 25, 2008, IAC Training Meeting, Geneva, Switzerland
The AMC Independent Assessment Committee (IAC) met for the
first time on 25 March 2008 to undergo a training session.
January 11, 2008, Third Economic Expert Group Meeting
The AMC Economic Expert Group met for the third time to discuss
AMC pricing and design issues.
December 17, 2007, TPP approval by Director General
of WHO, Geneva, Switzerland
The Target Product Profiles (TPP), endorsed by the Strategic
Advisory Group of Experts (SAGE) on 6 November 2007, are approved
by the Director General of World Health Organization (WHO).
The next step is endorsement by the AMC Independent Assessment
Committee (IAC) after which the TPP are considered final and
official.
November 21, 2007, UNICEF written declaration of
interest
UNICEF makes a written declaration of interest to operate
as procurement agent for the AMC.
November 20, 2007, IAC: selection of membership,
Geneva, Switzerland
The Independent Assessment Committee (IAC) selection panel
met for the second and finalized the selection of IAC members
according to criteria.
(PDF, 40Kb)
December 17, 2007, TPP approval by Director General
of WHO, Geneva, Switzerland
The Target Product Profiles (TPP), endorsed by the Strategic
Advisory Group of Experts (SAGE) on 6 November 2007, are approved
by the Director General of World Health Organization (WHO).
The next step is endorsement by the AMC Independent Assessment
Committee (IAC) after which the TPP are considered final and
official.
October 2, 2007, First IAC selection panel meeting,
Geneva, Switzerland
The Independent Assessment Committee (IAC) selection panel
met for the first time to select IAC members according to
specific criteria.
September 26-27, 2007, Second Economic Expert Group
Meeting, Washington D.C., US
The AMC Economic Expert Group met for the second time to discuss
AMC pricing and design issues.
September 11-12, 2007, Target Product Profiles (TPP)
committee meeting, World Health Organization, Geneva, Switzerland
The TPP expert group met to consider the draft TPP. Leading
up to the meeting, several subgroups worked on specific issues
and then came to conclusions on the draft TPP.
August 2-3, 2007, First Economic Expert Group Meeting,
Washington D.C., US
The AMC Economic Expert Group met for the first time to discuss
AMC pricing and design issues.
May 16, 2007, IAC call for applications, Geneva,
Switzerland
A call for applications for the AMC Independent Assessment
Committee (IAC) was issued on the AMC Website. This announcement
was also made public through specialized websites, relevant
newspapers and the GAVI Alliance’s extensive professional
contacts.
February 9, 2007, Launch of AMC, Rome, Italy
Canada, Italy, Norway, Russia, the United Kingdom, and the
Bill and Melinda Gates Foundation committed US$1.5 billion
to launch the first Advance Market Commitment (AMC) to help
speed the development and availability of a new vaccine which
is expected to save the lives of 5.4 million children by 2030.
The new initiative will target pneumoccal disease, a major
cause of pneumonia and meningitis that kills 1.6 million people
every year.
November 2006, Second Technical Working Group on
AMC, London, UK
Hosted by Her Majesty’s Treasury, the Technical Working Group
held its second meeting and reviewed the technical, institutional
and financial aspects of a pilot AMC for a pneumoccal vaccine.
September 7, 2006, First Technical Working Group
on AMC, Rome Italy
Hosted by the Italian Treasury, a Technical Working Group
composed by representatives from 15 potential donor countries,
a range of other institutions (such as the European Committee,
the World bank, the GAVI Alliance, the Gates Foundation and
the World Health Organisation) and industry representatives,
met for a first time and reviewed the technical, institutional
and financial aspects of a pilot AMC for a pneumococcal vaccine.
February 27-28, 2006: Disease Expert Committee make
recommendation on vaccine for AMC pilot, Paris France
An independent Expert Committee was convened to provide an
independent recommendation on which vaccine would be most
suitable for the initial AMC pilot. The recommended candidate
for the first AMC pilot is Pneumcoccal disease.
Pneumococcal disease kills around 1.6 million people a year,
most of them children. A successful AMC would prevent roughly
5.4 million deaths by 2030.
The Expert Committee also recommend a second AMC for a malaria
vaccine be explored to stimulate early research and development
investment, and to pilot the impact of the AMC on early stage
vaccines. A successful Malaria AMC would prevent roughly 2
million deaths by 2030.
January 2006: G7 Finance Ministers launch a constitution
process to advise on technical aspects of a pilot AMC
G7 Finance Ministers launch a consultation process to advise
on technical aspects of a pilot AMC. The World Bank and the
GAVI Alliance provide significant assistance on the design
of a pilot AMC. An Advisory Group brought together AMC stakeholders,
academics and technical experts in the global health community
to provide insight into the technical and structural options
for the pilot.
A Disease Expert Committee was also convened to provide an
independent recommendation on which vaccine would be most
suitable for the initial AMC pilot.
The advisory process concluded that AMCs are a feasible,
innovative, sustainable, cost-effective, results-oriented
and market-based tool in the fight against global disease
and poverty.
December 2, 2005: Tremonti Report to G8 Finance Ministers,
London, UK
At the G8 Meeting in London, the Italian Minister of Economy
and Finance, Guilio Tremonti, presented a report Background
papers to Advanced Market Commitments for Vaccines: A new
tool in the fight against disease and poverty.
April 2005: Publication of the ‘Making Markets for
Vaccines’ report
The center for Global Development (CGD) published the report
Making Markets for Vaccines: Ideas for Action, lead authors
Michael Kremer, Ruth Levine and Owen Barder.
The AMC (originally named “Pull Mechanisms”) working group
was a policy research group, convened by the Global Health
Policy Research Network at the CGD, to explore the feasibility
of advance guarantee agreements as a tool for stimulating
research, development and production of vaccines for neglected
developing-country diseases.
Funding for working group meetings, analytic work and consultations
was provided under a grant from the Bill & Melinda Gates
Foundation.
The CGD continued to work on the AMC idea and published additional
papers.
|
